ProfileGDS5678 / 1438266_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 32% 32% 32% 62% 32% 33% 36% 31% 32% 32% 32% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7798933
GSM967853U87-EV human glioblastoma xenograft - Control 22.7288432
GSM967854U87-EV human glioblastoma xenograft - Control 32.7334532
GSM967855U87-EV human glioblastoma xenograft - Control 42.6787332
GSM967856U87-EV human glioblastoma xenograft - Control 53.6472762
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8151432
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8128333
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8087536
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.680331
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7209232
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7170632
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6985432
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7265832
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7206332